Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Sutro Biopharma, Inc.NASDAQ: STRO

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of $8.51M (cash outflow) rose 72.0% year over year, ahead of the -93.9% change in trailing-twelve-month accounts receivables. Sequentially, it rose 15367.3% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.

Context

  • Accounts receivables amounted to 4.5% of revenue in FY2025, down 39.7 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +72.0% holds above the trailing-twelve-month pace of -93.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.51M+15367.3% QoQ
Last fiscal yearDec 2025
$4.64M-83.1% YoY
LTMMar 2026
$1.08M-93.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+72.0%——
1 year-83.1%——
3-year CAGR-4.6%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
4.64M USD
Year-over-year change
-83.1%

Accounts Receivables vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -93.9% is the 4th highest of 6, against a peer median of -87.7%.
  • Accounts receivables amounts to 1.1% of revenue for STRO, versus a peer median of 612.3%.
STRO Competitors
Accounts Receivables for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$5.47M USD-147.5%—12.1%
IFRXInflaRx N.V.LTM Mar 2026€1.95M EUR+3826.6%—6648.5%
STROSutro Biopharma, Inc.LTM Mar 2026$1.08M USD-93.9%-4.6%1.1%
CNTBConnect Biopharma Holdings LimitedFY2025$776K USD+198.4%+512.8%1212.5%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$183K USD-87.7%——
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$0 USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD———
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD-100.0%——
Peer median (excluding STRO) —-87.7%+512.8%612.3%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Depreciation & Amortization4.84M5.69M6.82M7.22M7.32M
Deferred Income Tax7.24M0000
Stock-Based Compensation23.24M26.3M24.91M24.69M14.01M
Change in Working Capital(17.62M)104.41M(34.38M)8.9M(50.4M)
Accounts Receivables(6.9M)5.34M(28.96M)27.46M4.64M
Inventory(4.55M)0000
Accounts Payables6.43M(1.23M)4.81M706K(2.47M)
Other Working Capital(12.61M)100.29M(10.23M)(19.27M)(52.57M)
Other Non-Cash Items6.16M(13.65M)(2.17M)(4.88M)42.92M
Operating Cash Flow(81.68M)3.55M(111.62M)(191.54M)(177.23M)
Capital Expenditures(15.32M)(7.86M)(4.32M)(3.1M)(1.7M)
Acquisitions (Net)028.74M000
Purchases of Investments(248.73M)(216.67M)(460.3M)(461.52M)(264.95M)
Sales of Investments166.73M189.5M460.69M683.13M311.66M
Other Investing Activities9K(28.73M)000
Investing Cash Flow(97.32M)(35.02M)(3.92M)218.51M45.01M
Debt Repayment0(9.38M)(12.5M)(4.08M)0
Common Stock Issued056.27M11.97M96.53M376K
Common Stock Repurchased(7K)0000
Dividends Paid00000
Other Financing Activities4.25M1.42M138.08M1.61M(332K)
Financing Cash Flow3.26M48.31M137.55M94.05M44K
Effect of Forex Changes00000
Net Change in Cash(175.74M)16.84M22.01M121.02M(132.17M)
Free Cash Flow(97M)(4.31M)(115.93M)(194.64M)(178.93M)

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.